Table 3.
Baseline characteristics of the 1 L ARROW trial participants given pralsetinib and Flatiron EDM cohort given 1 L pembrolizumab, and 1 L pembrolizumab with chemotherapy after IPTW-adjustment; balanced variables are those with SMD < 0.1.
| Level | Pembrolizumab | Pralsetinib | SMD | Pembrolizumab with chemotherapy | Pralsetinib | SMD | Adjusted | |
|---|---|---|---|---|---|---|---|---|
| ESS/n | 115/683 | 109/109 | 217/1270 | 109/109 | ||||
| Age (%) | <65 | 48.3 | 59.6 | 0.23 | 58.9 | 59.6 | 0.015 | Y |
| >=65 | 51.7 | 40.4 | 41.1 | 40.4 | ||||
| Sex (%) | F | 50.6 | 54.1 | 0.072 | 54.5 | 54.1 | 0.007 | Y |
| M | 49.4 | 45.9 | 45.5 | 45.9 | ||||
| Smoking history at baseline (%) | History of smoking | 48.9 | 39.4 | 0.192 | 40.3 | 39.4 | 0.017 | Y |
| No history of smoking | 51.1 | 60.6 | 59.7 | 60.6 | ||||
| ECOG (%) | 0 | 27.8 | 31.2 | 0.075 | 32.9 | 31.2 | 0.037 | Y |
| 72.2 | 68.8 | 67.1 | 68.8 | |||||
| Time from initial diagnosis to first dose (months) (median [IQR]) | 1 | 1.45 [0.92, 2.45] | 1.74 [1.25, 2.30] | 0.078 | 1.32 [0.92, 2.24] | 1.74 [1.25, 2.30] | 0.042 | Y |
| Stage at initial diagnosis (%) | STAGE I, II, or III | 17 | 15.6 | 0.038 | 16.6 | 15.6 | 0.028 | Y |
| STAGE IV | 83 | 84.4 | 83.4 | 84.4 | ||||
| Race (%) | White | 56.7 | 49.5 | 0.199 | 52.3 | 49.5 | 0.061 | Y |
| Other | 35.6 | 45 | 41.9 | 45 | ||||
| Unknown | 7.7 | 5.5 | 5.8 | 5.5 | ||||
| CNS metastases only (%) | 0 | 82.5 | 72.5 | 0.241 | 87.5 | 72.5 | 0.383 | N |
| 1 | 17.5 | 27.5 | 12.5 | 27.5 |
ESS Effective sample size; the sample size of an unweighted sample which incorporates the precision of the given weighted sample, n number of patients in remaining in IPTW-trimmed sample.